Differential 5mC/5hmC status in PCa
|
Prostate cell type (normal vs. cancer)
|
Overlapping methylation marks
|
Genomic region
|
---|
Intergenic
|
Genic
|
Exonic
|
Intronic
|
Promoter
|
CpG Island
|
RWPE-1 DNaseI hypersensitive sites
|
---|
5hmC “Absent”
|
RWPE-1
|
5hmC
|
0.051
|
0.666
|
<0.0001*,**
|
0.005*,***
|
<0.0001*,**
|
<0.0001*,**
|
<0.0001*,**
|
22Rv1
|
5mC
|
<0.0001*
|
0.311
|
0.002*,**
|
0.001*,***
|
<0.0001*,**
|
<0.0001*,**
|
<0.0001*,**
|
5hmC “Retained”
|
RWPE-1
|
5hmC
|
0.302
|
0.01
|
0.039
|
0.169
|
0.487
|
0.593
|
0.067
|
22Rv1
|
5hmC
|
0.013
|
0.547
|
0.452
|
0.834
|
0.115
|
0.001*
|
0.944
|
5hmC “Gained”
|
RWPE-1
|
5mC
|
0.003*,***
|
0.975
|
0.175
|
0.834
|
0.5
|
<0.0001*,**
|
0.007*
|
22Rv1
|
5hmC
|
<0.0001*,***
|
0.026
|
0.025
|
0.538
|
0.71
|
<0.0001*,**
|
0.511
|
- *Significant p values as determined by the chi-square test with Bonferroni correction for multiple testing applied; **5hmC is significantly more likely to be absent, gained, or retained within the given region than expected; ***5hmC is significantly less likely to be absent, gained, or retained within the given region than expected